Catalent, Inc. (CTLT)
Market Cap | 10.07B |
Revenue (ttm) | 4.83B |
Net Income (ttm) | 421.00M |
Shares Out | 179.96M |
EPS (ttm) | 2.35 |
PE Ratio | 23.29 |
Forward PE | 13.19 |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 177,806 |
Open | 54.03 |
Previous Close | 54.72 |
Day's Range | 55.35 - 56.69 |
52-Week Range | 40.69 - 115.34 |
Beta | 1.23 |
Analysts | Buy |
Price Target | 70.89 (+26.64%) |
Earnings Date | Feb 7, 2023 |
About CTLT
Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates through four segments: Biologics, Softgel and Oral Technologies, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary ... [Read more]
Full Company ProfileFinancial Performance
In 2022, Catalent's revenue was $4.83 billion, an increase of 20.76% compared to the previous year's $4.00 billion. Earnings were $503.00 million, a decrease of -4.91%.
Financial StatementsAnalyst Forecast
According to 22 analysts, the average rating for CTLT stock is "Buy." The 12-month stock price forecast is $70.89, which is an increase of 26.64% from the latest price.
News

Catalent (CTLT) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Catalent (CTLT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Catalent, Inc. Announces Second Quarter Fiscal Year 2023 Earnings Conference Webcast
SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the global leader in enabling pharma, biotech, and consumer health partners to optimize development, launch, and supply of better patien...

Catalent Appoints Ricardo Zayas as North American Biologics Operations Leader
SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced the appointment of Ricard...

Catalent's (CTLT) New Deal to Utilize Its Zydis ODT Technology
Catalent's (CTLT) latest development and license agreement is expected to accelerate the administration of therapeutic doses of active drugs.

Avantor® and Catalent Enter into Multi-Year Supply and Services Agreement
RADNOR, Pa. and SOMERSET, N.J.

Sarepta and Catalent Expand Strategic Manufacturing Partnership With Commercial Supply Agreement for Duchenne Muscular Dystrophy Gene Therapy Candidate
SOMERSET, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Catalent, Inc. (NYSE:CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, and Sarepta Therapeutic...

Catalent, Inc. to Present at the 41st Annual J.P. Morgan Healthcare Conference
SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the global leader in enabling pharma, biotech, and consumer health partners to optimize development, launch, and supply of better patien...

Catalent Announces Changes to its Board of Directors
SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the global leader in enabling pharma, biotech, and consumer health partners to optimize development, launch, and supply of better patien...

Catalent (CTLT) Expands Facility Capabilities in Shanghai
Catalent's (CTLT) latest capability expansion is expected to boost its business in the clinical trials space in its Asia-Pacific Clinical Supply Services network.

Bear Of The Day: Catalent (CTLT)
Earnings estimates have slipped for this stock following the most recent earnings miss.

After a $100 Haircut, is Catalent an Oversold Pharma Play?
With the macro backdrop weakening for Catalent's pharmaceutical and biotech customers, fundamental concerns could outweigh what the charts suggest.

Catalent, Inc. to Present at the Stephens Annual Investment Conference
SOMERSET, N.J.

Exelixis and Catalent Enter into New License Agreement for Three Antibody-Drug Conjugate Programs with the Potential to Accelerate Exelixis' Biologics Pipeline
ALAMEDA, Calif.

Catalent stock paces S&P 500 losers as it suffers record selloff after earnings miss, lowered outlook
Shares of Catalent Inc. CTLT, -23.31% plunged 23.4% toward a record one-day selloff, and enough to pace the S&P 500's SPX, -0.35% losers, after the contract drug manufacturing company reported fiscal ...

Catalent (CTLT) Q1 Earnings Lag Estimates, FY23 View Cut
Catalent (CTLT) records robust first-quarter fiscal 2023 results of its Pharma and Consumer Health segment despite overall soft performance.

Why Is Catalent (CTLT) Stock Down 24% Today?
Catalent (NYSE: CTLT) stock is falling hard on Tuesday as investors react to dismal results in its earnings report for the fiscal first quarter of 2023. The bad news for investors in CTLT stock start...

Catalent (CTLT) Q1 Earnings and Revenues Miss Estimates
Catalent (CTLT) delivered earnings and revenue surprises of -38.18% and 4.01%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Catalent, Inc. Reports First Quarter Fiscal 2023 Results
SOMERSET, N.J.

Analysts Estimate Catalent (CTLT) to Report a Decline in Earnings: What to Look Out for
Catalent (CTLT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Catalent, Inc. Announces First Quarter Fiscal Year 2023 Earnings Conference Webcast
SOMERSET, N.J.

New Strong Sell Stocks for October 14th
AHEXY, BLWYY, and CTLT have been added to the Zacks Rank #5 (Strong Sell) List on October 14, 2022.

JAZZ vs. CTLT: Which Stock Is the Better Value Option?
JAZZ vs. CTLT: Which Stock Is the Better Value Option?